New approaches in acute myeloid leukemia

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 29-41

  Blum, William ^a   Marcucci, Guido ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

acute myeloid leukemia; core binding factor; epigenetics; G3139 (oblimersen sodium, Genasense); KIT mutation; RAS mutation; ribonucleotide reductase; targeted therapy

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CD135 ANTIGEN; CLOFARABINE; CLORETAZINE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; GTI 2040; HISTONE DEACETYLASE INHIBITOR; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NUCLEOPHOSMIN; OBLIMERSEN; PANOBINOSTAT; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; ROMIDEPSIN; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VALSPODAR; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN-TYROSINE KINASES;

EID: 40749100947     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.009     Document Type: Review

References (73)

1. Mrozek K., Heerema N.A., and Bloomfield C.D. Cytogenetics in acute leukemia. Blood Reviews 18 (2004) 115-136
2. Mrozek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 109 (2007) 431-448
3. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. The New England Journal of Medicine 350 (2004) 1605-1616
4. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. The New England Journal of Medicine 350 (2004) 1617-1628
5. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 108 (2006) 1677-1683
6. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
7. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
8. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
9. Ghaddar H.M., Plunkett W., Kantarjian H.M., et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8 (1994) 1269-1274
10. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research 58 (1998) 4173-4179
11. Koo H.M., Monks A., Mikheev A., et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Research 56 (1996) 5211-5216
12. Koo H.M., McWilliams M.J., Alvord W.G., et al. Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Research 59 (1999) 6057-6062
13. Neubauer A., Maharry K., Marcucci G., et al. Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: a Cancer and Leukemia Group B (CALGB) study. Journal of Clinical Oncology 23 (2005) 563s [abstract 6514] Ref Type: Electronic Citation
14. Schlenk R.F., Dohner K., Pralle H., et al. Risk-adapted therapy in younger adults with acute myeloid leukemia: Results of the AMLHD98a trial of the AMLSG. Blood 108 (2006) 8a [abstract 14]
15. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106 (2005) 3658-3665
16. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
17. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
18. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
19. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
20. Stone R.M., Fischer T., Paquette R., et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood 108 (2006) 50a [abstract 157]
21. DeAngelo D.J., Amrein P.C., Kovacsocics T.J., et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 108 (2006) 51a [abstract 158]
22. DeAngelo D.J., Stone R.M., Heaney M.L., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108 (2006) 3674-3681
23. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Journal of Clinical Oncology 17 (1999) 3767-3775
24. Marcucci G., Mrozek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Journal of Clinical Oncology 23 (2005) 5705-5717
25. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. Journal of Clinical Oncology 24 (2006) 3904-3911
26. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 (2005) 2865-2870
27. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 (2006) 752-759
28. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. Journal of Clinical Oncology 23 (2005) 3971-3993
29. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research 66 (2006) 6361-6369
30. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
31. Blum W., Klisovic R.B., Hackanson B., et al. Clinical, pharmacokinetic, and pharmacodynamic results of a phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology (2007)
32. Cashen A., Schiller G.J., Larsen J.S., et al. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). Blood 108 (2006) 561a [abstract 1984]
33. End D.W., Smets G., Todd A.V., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research 61 (2001) 131-137
34. Lancet J.E., Gojo I., Gotlib J., et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109 (2007) 1387-1394
35. Harousseau J.L., Lancet J.E., Reiffers J., et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109 (2007) 5151-5156
36. Ishiguro K., Seow H.A., Penketh P.G., et al. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Molecular Cancer Therapeutics 5 (2006) 969-976
37. Baumann R.P., Seow H.A., Shyam K., et al. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncology Research 15 (2005) 313-325
38. Giles F., Verstovsek S., Faderl S., et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research 30 (2006) 1591-1595
39. Giles F., Rizzieri D., Karp J., et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology 25 (2007) 25-31
40. Wei X., Dai G., Liu Z., et al. Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. The AAPS Journal 8 (2006) E743-E755
41. Wei X., Dai G., Marcucci G., et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharmaceutical Research 23 (2006) 1251-1264
42. Klisovic R.B., Blum W., Wei X., et al. A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results. Blood 106 (2005) 782a [abstract 2790]
43. Gandhi V., Plunkett W., Bonate P.L., et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clinical Cancer Research 12 (2006) 4011-4017
44. Burnett A.K., Baccarani M., Johnson P., et al. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood 108 (2006) 130a [abstract 425]
45. Faderl S., Gandhi V., O'Brien S., et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105 (2005) 940-947
46. Debenham P.G., Kartner N., Siminovitch L., et al. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Molecular and Cellular Biology 2 (1982) 881-889
47. Nussler V., Pelka-Fleischer R., Zwierzina H., et al. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia 10 Suppl 3 (1996) S23-S31
48. List A.F., Spier C., Greer J., et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology 11 (1993) 1652-1660
49. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 (2002) 1224-1232
50. Friedenberg W.R., Rue M., Blood E.A., et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106 (2006) 830-838
51. Shimizu S., Eguchi Y., Kamiike W., et al. Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 12 (1996) 2251-2257
52. Capaccioli S., Quattrone A., Schiavone N., et al. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines. Oncogene 13 (1996) 105-115
53. Raveche E.S., Salerno E., Scaglione B.J., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109 (2007) 5079-5086
54. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 13944-13949
55. Calin G.A., Ferracin M., Cimmino A., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England Journal of Medicine 353 (2005) 1793-1801
56. Karakas T., Maurer U., Weidmann E., et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Annals of Oncology 9 (1998) 159-165
57. Marcucci G., Byrd J.C., Dai G., et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101 (2003) 425-432
58. Marcucci G., Stock W., Dai G., et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Journal of Clinical Oncology 23 (2005) 3404-3411
59. Marcucci G., Moser B., Blum W., et al. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. Journal of Clinical Oncology 25 (2007) 360s [abstract 7012]
60. Chang B.S., Kelekar A., Harris M.H., et al. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). Molecular and Cellular Biology 19 (1999) 6673-6681
61. Chauhan D., Velankar M., Brahmandam M., et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26 (2007) 2374-2380
62. Perez-Galan P., Roue G., Villamor N., et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 (2007) 4441-4449
63. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
64. Karp J.E., Passaniti A., Gojo I., et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical Cancer Research 11 (2005) 8403-8412
65. Karp J.E., Smith B.D., Levis M.J., et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clinical Cancer Research 13 (2007) 4467-4473
66. Attar E.C., De Angelo D.J., Sirulnik A., et al. Addition of bortezomib (velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate. Blood 106 (2005) 780a [abstract 2782]
67. Kell W.J., Burnett A.K., Chopra R., et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (2003) 4277-4283
68. Burnett A.K., Kell W.J., Goldstone A.H., et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 108 (2006) 8a [abstract 13]
69. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94 (1999) 3717-3721
70. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
71. Roboz G.J., Giles F.J., List A.F., et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20 (2006) 952-957
72. Karp J.E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research 10 (2004) 3577-3585
73. Kurtin S., and Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control 13 Suppl (2006) 26-31